In addition, there was a significant decrease in the relative promoter methylation of SRARP between 0.89‐ and 0.95‐fold in colon, liver, prostate, rectal, and endometrial cancers (P < 0.005; Fig. 3B and Table S3). The gene discussed is SRARP; the disease is endometrial cancer.